Are there any data to guide choice of immunotherapy agent in first line treatment for extensive stage small cell lung cancer?

Both the addition of durvalumab and atezolizumab to platinum etoposide resulted in a modest improvement in median progression free, overall survival and saw twelve-month overall survival rates just above 50%. The ECOG-ACRIN phase II trial of nivolumab added to platinum etoposide also improved PFS an...

The short answer is no, there is no comparative data that would allow us to distinguish any clinical difference between the two FDA-approved, first-line immune checkpoint inhibitors, atezolizumab or durvalumab, when used in combination with platinum plus etoposide for ES-SCLC. While cross-trial comp...

There are two checkpoint inhibitors, both targeting PD-L1, approved for use in the first-line setting for ES-SCLC and either would be appropriate in eligible patients. Atezolizumab was approved in March 2019 based on the IMpower 133 trial that demonstrated a significant improvement in survival when ...